home / stock / ions / ions articles
Friday, FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplonte...
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which...
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its holdings, with a significant sale of DraftKings Inc (NASDAQ:DKNG) shares an...
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-sta...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met...
Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicr...
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-ex...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...